Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MultiTAA-specific T cells for AML or MDS (ADSPAM)
NCT02494167Phase 1Completed
- Sponsor
- Baylor College of Medicine
- Start
- Feb 2016
- Primary completion
- Apr 2025
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of multiTAA-specific T cells in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Baylor College of Medicine. Primary endpoint: Dose-Limiting Toxicities at 4 weeks. Started Feb 2016; status: completed.
02
Drugs
multiTAA-specific T cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02494167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02494167.